GlassScriptPhysician profile
Jamie M Thompson
NPI 1902041981
$30,933.33
in general payments reported to CMS, 2019-2025
35 companies · $7,652 in 2025
The $7,652 reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,744 · 2022: $9,461 · 2023: $1,591 · 2024: $2,486 · 2025: $7,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,692 · Travel and Lodging: $2,197 · Consulting Fee: $1,750 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,691.80 |
| Travel and Lodging | $2,197.13 |
| Consulting Fee | $1,750.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,668.42 | 2021-2025 | |
| Gilead Sciences, INC. | $8,780.03 | 2021-2025 | Livdelzi, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,428.23 | 2021-2025 | Xifaxan, Trulance |
| Medtronic, INC. | $1,366.03 | 2021-2025 | Interstim |
| Janssen Biotech, INC. | $1,141.83 | 2021-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $527.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $426.94 | 2021-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $424.41 | 2021-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $297.58 | 2022-2025 | Ibsrela |
| Celgene Corporation | $260.47 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $239.88 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $187.96 | 2024-2025 | Vegzelma |
| Pfizer INC. | $170.09 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $168.71 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $156.32 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $148.66 | 2025 | Therasphere Administration Set |
| Ipsen Biopharmaceuticals, INC | $146.75 | 2025 | Iqirvo |
| Novo Nordisk INC | $138.56 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $138.38 | 2022-2025 | Rebyota |
| Daiichi Sankyo INC. | $124.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.72 | 2021 | |
| Genzyme Corporation | $115.80 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $97.90 | 2022 | |
| Qol Medical, LLC | $94.42 | 2021-2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $87.98 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $87.95 | 2021-2022 | |
| Orphalan INC | $72.47 | 2024-2025 | Cuvrior |
| Redhill Biopharma INC. | $58.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57.15 | 2024 | Dificid |
| Aimmune Therapeutics, INC. | $54.86 | 2024-2025 | Vowst |
| Braintree Laboratories, INC. | $53.47 | 2021-2025 | Suflave |
| Mallinckrodt Hospital Products INC. | $25.54 | 2025 | Terlivaz |
| Exact Sciences Corporation | $24.06 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $19.52 | 2023 | Amjevita |
| Organon LLC | $17.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.